EUVIMEDEUVIMED entdecken
Crossref

CRISPR ‐Cas9 lipid nanoparticles for targeting cyclin‐dependent kinases in the tumor microenvironment

Mohammad Mashreghi iD, Mahere Rezazade Bazaz, Mahmoud Reza Jaafari iD

Biotechnology Progress · 2026

DOI: 10.1002/btpr.70105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Progress, 2026. Verfasst von Mohammad Mashreghi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Nanoparticles, CRISPR-Cas Systems, Tumor Microenvironment, Lipids. Die Arbeit nennt 37 Literaturangaben. Gefördert von: National Institute for Medical Research Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Due to the significant roles of cyclin‐dependent kinases 4 and 6 (CDK4/6) in cancer progression, this study aimed to introduce clustered regularly interspaced short palindromic repeats (CRISPR)‐CRISPR‐associated protein 9 (Cas9) plasmid DNA (pDNA) encapsulated in lipid nanoparticles (LNPs) as a novel CDK4/6 inhibitor using a gene knock‐out strategy for treating cancer. pDNA‐LNP was prepared and characterized using a microfluidic system. The results indicated the hydrodynamic diameter of the pDNA‐LNP was 90.0 ± 0.1 nm with the PDI of 0.1 and a negative zeta‐potential. The cytotoxicity results demonstrated statistically significant differences at doses of 0.250, 500, and 1 μg of pDNA with the capabilities of pDNA‐LNP in the induction of apoptosis, as depicted by the Annexin‐V‐FITC‐PI method. Real‐time quantitative PCR (qPCR) also indicated a significant reduction in the expression levels of both CDK4 and 6 in the cells that were treated with pDNA‐LNP. The in vivo anti‐tumor activities of pDNA‐LNP have demonstrated that the formulation has the potential to decrease tumor size and improve survival parameters, including median survival time (MST), which was increased from 31 days for the PBS group to 51 days for the pDNA‐LNP group at 0.5 μg. On the other hand, the dose of 1 μg had shown signs of toxicity, indicating the need to optimize dosing in future studies. In summary, these findings indicate that CRISPR‐Cas9 encapsulated in the LNP can suppress tumor growth and offer a promising strategy for future cancer treatment approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesCRISPR-Cas SystemsTumor MicroenvironmentLipidsCyclin-Dependent Kinase 4Cyclin-Dependent KinasesAnimalsHumansCell Line, TumorMiceApoptosisGene Therapy AgentsLiposomes

Stichwörter der Autor:innen

CRISPR‐Cas9cancer therapycyclin‐dependent kinaseslipid nanoparticles

Substanzen

LipidsCyclin-Dependent Kinase 4Cyclin-Dependent KinasesLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Stem Cell Biology and Regenerative Medicine Research Group, Research Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
  • Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

ORCID-Profile: Mohammad Mashreghi, Mahmoud Reza Jaafari

Förderung

  • National Institute for Medical Research Development

Zitieren

APA

Mashreghi, M., Rezazade Bazaz, M., & Jaafari, M. R. (2026). CRISPR ‐Cas9 lipid nanoparticles for targeting cyclin‐dependent kinases in the tumor microenvironment. Biotechnology Progress. https://doi.org/10.1002/btpr.70105

Vancouver

Mashreghi M, Rezazade Bazaz M, Jaafari MR. CRISPR ‐Cas9 lipid nanoparticles for targeting cyclin‐dependent kinases in the tumor microenvironment. Biotechnology Progress. 2026. doi:10.1002/btpr.70105

BibTeX
@article{Mashreghi2026,
  author = {Mashreghi, Mohammad and Rezazade Bazaz, Mahere and Jaafari, Mahmoud Reza},
  title = {CRISPR ‐Cas9 lipid nanoparticles for targeting cyclin‐dependent kinases in the tumor microenvironment},
  journal = {Biotechnology Progress},
  year = {2026},
  doi = {10.1002/btpr.70105}
}
Kostenlos starten →